Product Information
- Pirtobrutinib
LOXO-305 is a small molecule that inhibits the activity of venetoclax, an inhibitor of BCL2. LOXO-305 has shown efficacy in mouse models for chronic lymphocytic leukemia, which is a type of cancer that originates in white blood cells called lymphocytes. Venetoclax targets the BCL2 protein and inhibits its ability to keep lymphocytes from dying, and thus is used to treat chronic lymphocytic leukemia. Venetoclax also has minimal activity against other types of cancer cells, including those that are resistant to chemotherapy drugs such as doxorubicin or cisplatin. The safety profile for LOXO-305 is also very good with no observed toxicity in mice or monkeys up to doses of 500 mg/kg. This drug has been shown to be potently active in cellular models at concentrations below 10 μM, which may be due to inhibition of the venetoclax target or inhibition of other proteins involved in
Chemical properties
Technical inquiry about: 3D-BL180882 LOXO-305
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
